Ferring Pharmaceuticals made a US$30 million investment announcement of expanding its capabilities in biologics through a new biotech centre at its global headquarters and manufacturing site in St Prex, Switzerland.
Ferring Pharmaceuticals is planning to integrate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities at its new biotech center in Switzerland.
The manufacturing capabilities of the company will include API - Active Pharmaceutical Ingredient for follitropin delta along with latest fertility treatment.
Ferring Pharma Company is committed to investing in innovative technology platforms to create new solutions for patients in the core areas of reproductive medicine, women’s health, gastroenterology, and urology.
The company’s expansion investment in state-of-the-art manufacturing and development technologies will get completed by next three years.
Ferring had announced a tie-up with Ligand Pharmaceuticals to use Ligand’s OmniAb platform to explore new human monoclonal antibodies in order to fulfill the patient needs in urology, gastroenterology, and other reproductive medicines.
|St. Prex, Switzerland
|Ferring Pharmaceuticals, Ligand Pharmaceuticals